Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferative. 4) quercetin and imatinib were potent dual vasodilator/antiproliferative drugs. 5) Tacrolimus and levosimendan lacked antiproliferative effects. 6) Forskolin, pinacidil and hydroxyfasudil were more effective as antiproliferative in human cells.PMID:38599357 | DOI:10.1016/j.vph.2024.107371
Source: Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
More News: Drugs & Pharmacology | Gleevec | Hypertension | Nifedipine | Prograf | Pulmonary Hypertension | Study | Tacrolimus